Navigation Links
PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL
Date:5/30/2008

n, affecting less than 200,000 individuals in the United States.(1)

Eltrombopag is an investigational, once-daily oral treatment developed to induce the production of cells in the bone marrow to increase platelets, which are critical in minimizing the incidence of bleeding in chronic ITP.

Eltrombopag, a novel oral thrombopoeitin (TPO) receptor agonist, if approved, would be the first oral short-term treatment of previously treated patients with chronic ITP to increase platelet counts and reduce or prevent bleeding.

In the pivotal studies, the most common adverse events observed in patients taking eltrombopag were headache, nasopharyngitis, and nausea.

About the data

The NDA submission is supported by the largest database of clinical trial information on investigational therapies for chronic ITP patients. Two pivotal trials (one Phase III trial and one Phase II trial), were submitted to support the filing.

About ITP

Chronic ITP is a disorder marked by increased platelet destruction and/or inadequate platelet production in the blood, which causes an increased risk of bruising and bleeding.(2,3) There are estimated to be approximately 60,000 individuals diagnosed with chronic ITP in the U.S.(4) People with chronic ITP often bleed from small blood vessels causing bruises, nosebleeds or even fatal gastrointestinal or intra cerebral bleeds, although these are rare.(3)

About Eltrombopag

Eltrombopag is an oral, non-peptide thrombopoietin receptor agonist that has been shown in pre-clinical research and clinical trials to stimulate the proliferation and differentiation of megakaryocytes, the bone marrow cells that give rise to blood platelets. Eltrombopag was discovered as a result of research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals (Nasdaq:

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder
2. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
3. DaVita Receives Civil Complaint
4. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
5. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
6. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
7. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
8. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
9. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
10. Prime Therapeutics Receives TIPPS Certification
11. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... CA (PRWEB) August 21, 2014 AttorneyOne.com, ... regarding all the latest information from the FDA on ... , The US FDA announced on August 15, that ... Solution with 2.5% Dextrose 5000mL (Ambu-Flex II), by Baxter ... presence of particulate matter. , The reason for ...
(Date:8/21/2014)... 21, 2014 Inc. magazine ranked Centurion ... 500|5000, an exclusive ranking of the nation's fastest-growing private ... the most important segment of the economy—America’s independent entrepreneurs. ... LinkedIn, Zillow, and many other well-known names gained early ... is proud to have been named to the Inc. ...
(Date:8/21/2014)... Washington Crossing, PA (PRWEB) August 21, 2014 ... at Washington Crossing Historic Park in Washington Crossing, Pennsylvania ... to maintain the park. “We have been looking for ... community organizations,” said Matt Kiernan, Partner with Pharmica Consulting. ... a significant part of U.S. history, we jumped at ...
(Date:8/21/2014)... 2014 The Rottenstein Law Group LLP, ... years of experience advocating for plaintiffs with claims of ... devices, announces the launch of its new website, ... believe they have been harmed by prescription drugs or ... the severe adverse side effects suffered by women allegedly ...
(Date:8/21/2014)... She was 12 years old when the unthinkable happened ... to correct her frequent headaches failed. , In her ... shares her journey of overcoming devastating obstacles involving dual disability, ... of justice for years. , “My faith in God ... the light,” Strom-Stewart said. “But it took me more than ...
Breaking Medicine News(10 mins):Health News:Dianeal Low Calcium (2.5mEq/L) Peritoneal Dialysis Solution with 2.5% Dextrose 5000mL (Ambu-Flex II) Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 2Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 3Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 4Health News:Pharmica Spends the Day Helping to Preserve Washington Crossing Historic Park 2Health News:Rottenstein Law Group LLP Announces Launch of WeHelpWomen.com 2Health News:The Dramatic, Uplifting Story from a Brain Injured Woman 2
... ANTONIO - Breast cancer is a multifaceted disease requiring ... adjuvant therapies. Data presented at the CTRC-AACR San Antonio ... Hormone Supplements Reduce Death from Breast Cancer , ... have been implicated in increased rates of breast cancer, ...
... are victorious in sham SEIU vote , Less ... while caregivers file over 125,000 protests , ... in a statewide vote of healthcare workers conducted by the ... workers overwhelmingly oppose their national union,s sham election. Ballots were ...
... shows , , FRIDAY, Dec. 12 (HealthDay News) -- ... their breast cancer returning after surgery may make ... difficult, a new study concludes. , Doctors typically ... on a standard risk-assessment tool, with four different ...
... just announced her resignation as President of the Texas Medical ... power by the TMB against good physicians. Kalafut,s tenure ... and stonewalling by the TMB and Governor Rick Perry. , ... said AAPS Executive Director Jane Orient. "AAPS has received ...
... for America,s Health (TFAH) commends the Institute of Medicine for their ... Century: Charting a New Course for a Healthier America ... federal government is responsible for protecting the health of Americans, but ... fixed," said Jeff Levi, PhD, Executive Director of TFAH. "The ...
... 12th annual holiday gala The,Teddy Bear Ball, The ... Steve,Mosko, President of Sony Pictures Television in recognition ... with special needs. Grammy(R),winning singer-songwriter Kenny Loggins electrified ... Heart. Long standing friend and colleague of,nearly 30 ...
Cached Medicine News:Health News:Patient management: Quality of life and beyond 2Health News:Free Choice? Not For SEIU Members in California 2Health News:Risk Info for Breast Cancer Patients Too Confusing 2Health News:AAPS Applauds the Resignation of TMB President Roberta Kalafut, Mari Robinson Should Resign Next 2Health News:Trust for America's Health Applauds New IOM Report on Improving the U.S. Department of Health and Human Services for the 21st Century 2Health News:The Help Group's Teddy Bear Ball Salutes Sony Pictures Television President, Steve Mosko and Features Performance by Kenny Loggins 2
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com ... available in its catalogue: The Market ... http://www.reportlinker.com/p02051938/The-Market-for-Medical-Devices-in-EMEA .html The European, Middle Eastern and ... medical devices. As part of its coverage, this ... concentrates on the EMEA medical device markets and ...
(Date:8/20/2014)... Aug 20, 2014 Reportlinker.com announces that ... its catalogue: Global Patient Scales Industry ... This report analyzes the worldwide markets for Patient ... Segments: Floor Scales, Infant & Baby Scales, Chair ... separate comprehensive analytics for the US, Canada, Japan, ...
(Date:8/20/2014)... 20, 2014 Glenmark Pharmaceuticals ... Pharmaceuticals Limited India (GPL), announces the discovery and ... clinical development candidate, GBR 1302, a HER2xCD3 bispecific ... the Glenmark Biologics Research Centre located in La ... is based on Glenmark,s innovative BEAT antibody technology ...
Breaking Medicine Technology:The Market for Medical Devices in EMEA 2The Market for Medical Devices in EMEA 3The Market for Medical Devices in EMEA 4The Market for Medical Devices in EMEA 5Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3
... Risk Frontline Elderly AML and in Combination with Cytarabine in Relapsed/Refractory ... for Tuesday, December 9 at 11:00 am ET to Discuss Phase ... , SAN FRANCISCO , Dec. 7 Sunesis ... of new data from two ongoing clinical trials demonstrating that the ...
... Dec. 6 Results from RESTORE 2, a,placebo-controlled, Phase ... the number of seizures in adult,patients with refractory partial-onset ... added to a patient,s current anti-epileptic drug (AED) therapy. ... experiencing,seizures despite taking stable doses of up to three ...
Cached Medicine Technology:Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 2Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 3Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 4Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 5Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 6Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 2Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 3Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 4Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 5
Passive heat and moisture exchangers for respiratory applications....
Ballard trach care HMES and filters, tv1000, HME...
Ballard trach care HMES and filters, tv 500, HME...
Indications For Usage:, ,Single use on tracheostomy patients who can breathe spontaneously. The product is intended to be replaced at least once every 24 hours....
Medicine Products: